Fatro
Prinovox 40 mg + 4 mg - cats under 4kg - 6 pipettes

Treatment of flea and tick infestations in cats and dogs

Prescription required* (Exceptions apply)

Prinovox is a clear, yellow to brownish spot-on solution for cats, ferrets and dogs.

Each Prinovox pipette contains:

  • Active Substance:
Name Imidacloprid Moxidectin
Prinovox 40 mg + 4 mg spot-on solution for small cats and ferrets 40.00 mg 4.0 mg
Prinovox 40 mg + 10 mg spot-on solution for small dogs 40.00 mg 10.0 mg
Prinovox 80 mg + 8 mg spot-on solution for large cats 80.00 mg 8.0 mg
Prinovox 100 mg + 25 mg spot-on solution for medium dogs 100.00 mg 25.0 mg
Prinovox 250 mg + 62.5 mg spot-on solution for large dogs 250.00 mg 62.5 mg
Prinovox 400 mg + 100 mg spot-on solution for extra-large dogs 400.00 mg 100.0 mg
  • List of excipients:
    • Butylhydroxytoluene (E 321)
    • Benzyl alcohol
    • Propylene carbonate

Indications for use of Prinovox, specifying the target species:

  • For cats suffering from, or at risk from, mixed parasitic infections:
    • The treatment and prevention of flea infestation (Ctenocephalides felis)
    • The treatment of ear mite infestation (Otodectes cynotis)
    • The treatment of notoedric mange (Notoedres cati)
    • The treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults).
    • The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis)
    • The treatment of infections with gastrointestinal nematodes (L4 larvae immature adults and adults of Toxocara cati and Ancylostoma tubaeforme). The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
  • For ferrets suffering from, or at risk from, mixed parasitic infections:
    • Treatment and prevention of flea infestation (Ctenocephalides felis)
    • The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).
  • For dogs suffering from, or at risk from, mixed parasitic infections:
    • The treatment and prevention of flea infestation (Ctenocephalides felis)
    • The treatment of biting lice (Trichodectes canis)
    • The treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis)
    • The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis)
    • The treatment of circulating microfilariae (Dirofilaria immitis),
    • The treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens)
    • The prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens)
    • The reduction of circulating microfilariae (Dirofilaria repens)
    • The prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum),
    • The treatment of Angiostrongylus vasorum and Crenosoma vulpis
    • The prevention of spirocercosis (Spirocerca lupi)
    • The treatment of Eucoleus (syn. Capillaria) boehmi (adults)
    • The treatment of the eye worm Thelazia callipaeda (adults)
    • The treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis).
    • The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
  • Do not use in kittens under 9 weeks of age.
  • Do not use in puppies under 7 weeks of age.
  • Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.
  • Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group.
  • For ferrets: Do not use Prinovox for large cats (0.8 ml) or Prinovox for dogs (any size).
  • For dogs, the corresponding “Prinovox for dogs” product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used.
  • Do not use on canaries.

Amounts of Prinovox to be administered and administration route:

  • For external use only.
  • The body weight of treated animal should be determined prior to treatment.
  • The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
  • Method of administration:
    • Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette.
    • Cats and ferrets:
    • Part the fur on the animal's neck at the base of the skull until the skin is visible. Application at the base of the skull will minimise the opportunity for the animal to lick the product.
    • Dogs:
    • With the animal in a standing position, part the coat between the shoulder blades until the skin is visible.
    • Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Apply only to undamaged skin.

Dosage schedule for cats:

  • The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1 ml of this product per kg bodyweight.
Weight of cat [kg] Pipette size to be used Volume [ml] Imidacloprid [mg/kg bw] Moxidectin [mg/kg bw]
≤ 4 kg Prinovox for small cats and ferrets 0.4 minimum of 10 minimum of 1
> 4–8 kg Prinovox for large cats 0.8 10–20 1–2
> 4–8 kg The appropriate combination of pipettes
  • Flea treatment and prevention (Ctenocephalides felis):
    • One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine the treatment with this product with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy.
  • Treatment of ear mite infestation (Otodectes cynotis):
    • A single dose of the product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
  • Treatment of notoedric mange (Notoedres cati):
    • A single dose of the product should be administered.
  • Treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults):
    • A single dose of the product should be administered.
  • Heartworm prevention (Dirofilaria immitis):
    • Cats in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with this product.
    • For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with this product must be given within 1 month of the last dose of the former medication.
    • In non-endemic areas there should be no risk of cats having heartworm. Therefore they can be treated without special precautions.
  • Roundworm and hookworm treatment:
    • In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas nonendemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Dosage schedule for ferrets:

  • One 0.4 ml pipette of this product should be administered per animal. Do not exceed the recommended dose. The treatment schedule should be based on the local epidemiological situation.
  • Flea treatment and prevention (Ctenocephalides felis):
    • One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat administration after 2 weeks.
  • Heartworm prevention (Dirofilaria immitis):
    • Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with this product, the advice provided in section 4.5 should be considered.
    • For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.
    • In non-endemic areas there should be no risk of ferrets having heartworm. Therefore they can be treated without special precautions.

Dosage schedule for dogs:

  • The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml of this product per kg bodyweight.
Weight of dog [kg] Pipette size to be used Volume [ml] Imidacloprid [mg/kg bw] Moxidectin [mg/kg bw]
≤ 4 kg Prinovox for small dogs 0.4 minimum of 10 minimum of 2.5
> 4–10 kg Prinovox for medium dogs 1.0 10–25 2.5–6.25
> 10–25 kg Prinovox for large dogs 2.5 10–25 2.5–6.25
> 25–40 kg Prinovox for extra-large dogs 4.0 10–16 2.5–4
> 40 kg The appropriate combination of pipettes
  • Flea treatment and prevention (Ctenocephalides felis):
    • One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine the treatment with the product with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.
  • Treatment of biting lice (Trichodectes canis):
    • A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
  • Treatment of ear mite infestation (Otodectes cynotis):
    • A single dose of the product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
  • Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis):
    • A single dose should be administered twice 4 weeks apart.
  • Treatment of demodicosis (caused by Demodex canis):
    • The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, the product can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.
    • As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
  • Prevention of heartworm disease (D. immitis) and cutaneous dirofilariosis (D. repens):
    • Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with this product, the advice provided in section 4.5 should be considered.
    • For prevention of heartworm disease and cutaneous dirofilariosis, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit D. immitis and D. repens larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with this product must be given within 1 month of the last dose of the former medication.
    • In non-endemic areas there should be no risk of dogs having heartworm. Therefore they can be treated without special precautions.
  • Treatment of microfilariae (D. immitis):
    • The product should be administered monthly for two consecutive months.
  • Treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens):
    • The product should be administered monthly for six consecutive months.
  • Reduction of microfilariae ( D. repens):
    • The product should be administered monthly for four consecutive months.
  • Treatment and prevention of Angiostrongylus vasorum:
    • A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. In endemic areas regular monthly applications will prevent angiostrongylosis and patent infection with Angiostrongylus vasorum.
  • Treatment of Crenosoma vulpis
    • A single dose should be administered.
  • Prevention of Spirocerca lupi:
    • The product should be administered monthly.
  • Treatment of Eucoleus (syn. Capillaria) boehmi (adults)
    • The product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.
  • Treatment of the eye worm Thelazia callipaeda (adults):
    • A single dose of the product should be administered.
  • Roundworm, hookworm and whipworm treatment:
    • In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas nonendemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.
    • Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala.

Prinovox is a clear, yellow to brownish spot-on solution for cats, ferrets and dogs.

Each Prinovox pipette contains:

  • Active Substance:
Name Imidacloprid Moxidectin
Prinovox 40 mg + 4 mg spot-on solution for small cats and ferrets 40.00 mg 4.0 mg
Prinovox 40 mg + 10 mg spot-on solution for small dogs 40.00 mg 10.0 mg
Prinovox 80 mg + 8 mg spot-on solution for large cats 80.00 mg 8.0 mg
Prinovox 100 mg + 25 mg spot-on solution for medium dogs 100.00 mg 25.0 mg
Prinovox 250 mg + 62.5 mg spot-on solution for large dogs 250.00 mg 62.5 mg
Prinovox 400 mg + 100 mg spot-on solution for extra-large dogs 400.00 mg 100.0 mg
  • List of excipients:
    • Butylhydroxytoluene (E 321)
    • Benzyl alcohol
    • Propylene carbonate

Indications for use of Prinovox, specifying the target species:

  • For cats suffering from, or at risk from, mixed parasitic infections:
    • The treatment and prevention of flea infestation (Ctenocephalides felis)
    • The treatment of ear mite infestation (Otodectes cynotis)
    • The treatment of notoedric mange (Notoedres cati)
    • The treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults).
    • The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis)
    • The treatment of infections with gastrointestinal nematodes (L4 larvae immature adults and adults of Toxocara cati and Ancylostoma tubaeforme). The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
  • For ferrets suffering from, or at risk from, mixed parasitic infections:
    • Treatment and prevention of flea infestation (Ctenocephalides felis)
    • The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).
  • For dogs suffering from, or at risk from, mixed parasitic infections:
    • The treatment and prevention of flea infestation (Ctenocephalides felis)
    • The treatment of biting lice (Trichodectes canis)
    • The treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis)
    • The prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis)
    • The treatment of circulating microfilariae (Dirofilaria immitis),
    • The treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens)
    • The prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens)
    • The reduction of circulating microfilariae (Dirofilaria repens)
    • The prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum),
    • The treatment of Angiostrongylus vasorum and Crenosoma vulpis
    • The prevention of spirocercosis (Spirocerca lupi)
    • The treatment of Eucoleus (syn. Capillaria) boehmi (adults)
    • The treatment of the eye worm Thelazia callipaeda (adults)
    • The treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis).
    • The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
  • Do not use in kittens under 9 weeks of age.
  • Do not use in puppies under 7 weeks of age.
  • Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.
  • Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group.
  • For ferrets: Do not use Prinovox for large cats (0.8 ml) or Prinovox for dogs (any size).
  • For dogs, the corresponding “Prinovox for dogs” product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used.
  • Do not use on canaries.

Amounts of Prinovox to be administered and administration route:

  • For external use only.
  • The body weight of treated animal should be determined prior to treatment.
  • The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
  • Method of administration:
    • Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette.
    • Cats and ferrets:
    • Part the fur on the animal's neck at the base of the skull until the skin is visible. Application at the base of the skull will minimise the opportunity for the animal to lick the product.
    • Dogs:
    • With the animal in a standing position, part the coat between the shoulder blades until the skin is visible.
    • Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Apply only to undamaged skin.

Dosage schedule for cats:

  • The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1 ml of this product per kg bodyweight.
Weight of cat [kg] Pipette size to be used Volume [ml] Imidacloprid [mg/kg bw] Moxidectin [mg/kg bw]
≤ 4 kg Prinovox for small cats and ferrets 0.4 minimum of 10 minimum of 1
> 4–8 kg Prinovox for large cats 0.8 10–20 1–2
> 4–8 kg The appropriate combination of pipettes
  • Flea treatment and prevention (Ctenocephalides felis):
    • One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine the treatment with this product with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy.
  • Treatment of ear mite infestation (Otodectes cynotis):
    • A single dose of the product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
  • Treatment of notoedric mange (Notoedres cati):
    • A single dose of the product should be administered.
  • Treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults):
    • A single dose of the product should be administered.
  • Heartworm prevention (Dirofilaria immitis):
    • Cats in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with this product.
    • For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with this product must be given within 1 month of the last dose of the former medication.
    • In non-endemic areas there should be no risk of cats having heartworm. Therefore they can be treated without special precautions.
  • Roundworm and hookworm treatment:
    • In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas nonendemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Dosage schedule for ferrets:

  • One 0.4 ml pipette of this product should be administered per animal. Do not exceed the recommended dose. The treatment schedule should be based on the local epidemiological situation.
  • Flea treatment and prevention (Ctenocephalides felis):
    • One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat administration after 2 weeks.
  • Heartworm prevention (Dirofilaria immitis):
    • Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with this product, the advice provided in section 4.5 should be considered.
    • For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.
    • In non-endemic areas there should be no risk of ferrets having heartworm. Therefore they can be treated without special precautions.

Dosage schedule for dogs:

  • The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml of this product per kg bodyweight.
Weight of dog [kg] Pipette size to be used Volume [ml] Imidacloprid [mg/kg bw] Moxidectin [mg/kg bw]
≤ 4 kg Prinovox for small dogs 0.4 minimum of 10 minimum of 2.5
> 4–10 kg Prinovox for medium dogs 1.0 10–25 2.5–6.25
> 10–25 kg Prinovox for large dogs 2.5 10–25 2.5–6.25
> 25–40 kg Prinovox for extra-large dogs 4.0 10–16 2.5–4
> 40 kg The appropriate combination of pipettes
  • Flea treatment and prevention (Ctenocephalides felis):
    • One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine the treatment with the product with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.
  • Treatment of biting lice (Trichodectes canis):
    • A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
  • Treatment of ear mite infestation (Otodectes cynotis):
    • A single dose of the product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
  • Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis):
    • A single dose should be administered twice 4 weeks apart.
  • Treatment of demodicosis (caused by Demodex canis):
    • The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, the product can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.
    • As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
  • Prevention of heartworm disease (D. immitis) and cutaneous dirofilariosis (D. repens):
    • Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with this product, the advice provided in section 4.5 should be considered.
    • For prevention of heartworm disease and cutaneous dirofilariosis, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit D. immitis and D. repens larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with this product must be given within 1 month of the last dose of the former medication.
    • In non-endemic areas there should be no risk of dogs having heartworm. Therefore they can be treated without special precautions.
  • Treatment of microfilariae (D. immitis):
    • The product should be administered monthly for two consecutive months.
  • Treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens):
    • The product should be administered monthly for six consecutive months.
  • Reduction of microfilariae ( D. repens):
    • The product should be administered monthly for four consecutive months.
  • Treatment and prevention of Angiostrongylus vasorum:
    • A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. In endemic areas regular monthly applications will prevent angiostrongylosis and patent infection with Angiostrongylus vasorum.
  • Treatment of Crenosoma vulpis
    • A single dose should be administered.
  • Prevention of Spirocerca lupi:
    • The product should be administered monthly.
  • Treatment of Eucoleus (syn. Capillaria) boehmi (adults)
    • The product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.
  • Treatment of the eye worm Thelazia callipaeda (adults):
    • A single dose of the product should be administered.
  • Roundworm, hookworm and whipworm treatment:
    • In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas nonendemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.
    • Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala.
53.70
Order within 1h 35m 1s (before 12AM)
And receive your order
on Friday 14 December
AIR FREIGHT

Customers who buy this product, usually buy: